BeOne Medicines (NASDAQ:ONC) Price Target Raised to $412.00

BeOne Medicines (NASDAQ:ONC) had its target price lifted by Truist Financial from $400.00 to $412.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also issued reports on the stock. Citigroup upped their target price on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, January 21st. Morgan Stanley restated an “overweight” rating and set a $405.00 target price on shares of BeOne Medicines in a research report on Thursday, January 8th. Guggenheim lifted their target price on shares of BeOne Medicines from $400.00 to $410.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Sanford C. Bernstein upgraded BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target for the company in a report on Monday, January 12th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $394.25.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $316.99 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The business’s fifty day moving average price is $336.81 and its two-hundred day moving average price is $330.87. The stock has a market cap of $34.76 billion, a PE ratio of 125.79 and a beta of 0.53. BeOne Medicines has a one year low of $196.45 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. On average, analysts forecast that BeOne Medicines will post -5.82 EPS for the current fiscal year.

Insider Transactions at BeOne Medicines

In other news, SVP Chan Henry Lee sold 1,660 shares of BeOne Medicines stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total value of $580,203.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO John Oyler sold 75,631 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $307.79, for a total value of $23,278,465.49. Following the sale, the chief executive officer owned 24,369 shares of the company’s stock, valued at $7,500,534.51. The trade was a 75.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 102,656 shares of company stock worth $31,567,496. Company insiders own 6.62% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently made changes to their positions in the business. Primecap Management Co. CA purchased a new stake in BeOne Medicines during the 2nd quarter worth $1,231,720,000. Temasek Holdings Private Ltd acquired a new position in shares of BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP purchased a new stake in shares of BeOne Medicines in the second quarter worth about $113,190,000. Baird Financial Group Inc. acquired a new stake in shares of BeOne Medicines in the second quarter valued at about $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $73,347,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.